Fig. 4: BET inhibitors enhance the effects of BRAF/MEK inhibitors in BRAF-mutant melanoma. | British Journal of Cancer

Fig. 4: BET inhibitors enhance the effects of BRAF/MEK inhibitors in BRAF-mutant melanoma.

From: Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma

Fig. 4: BET inhibitors enhance the effects of BRAF/MEK inhibitors in BRAF-mutant melanoma.The alternative text for this image may have been generated using AI.

a Colony assay for BRAF-mutant human melanoma cell lines, A375, 1205Lu, and M238 after 2 weeks of combination treatment using BRAFi/MEKi (dabrafenib, 50 nM + trametinib, 5 nM) ± BETi (either JQ1, 1 μM or PLX51107, 2 μM). Magnification: ×20. b S-phase cell cycle arrest detection by EdU staining for A375, 1205Lu and M238 cells after treatment with BRAFi/MEKi ± BETi over a time course (24–72 h). Tukey’s test (*p < 0.05, ***p < 0.001, ****p < 0.0001). c Cell proliferation curves by IncuCyte® assay over 3 weeks of combination treatment using BRAFi/MEKi ± BETi (PLX51107, 2 μM) for the cell lines A375 and 1205Lu. Tukey’s test (***p < 0.001, ****p < 0.0001).

Back to article page